Urist Marshall 4
4 · Royalty Pharma plc · Filed Jul 2, 2026
Research Summary
AI-generated summary of this filing
Royalty Pharma EVP Urist Marshall Sells 9,099 Shares
What Happened
Urist Marshall, Executive Vice President of Research & Investments at Royalty Pharma (RPRX), sold 9,099 shares on 2026-07-01. The shares were disposed at a weighted average price of $55.88 per share for total proceeds of approximately $508,454. The filing lists the transaction as an open market or private sale (code S).
Key Details
- Transaction date: 2026-07-01 (reported on Form 4 filed 2026-07-02) — timely filing.
- Price: weighted average $55.88; actual sale prices ranged from $55.69 to $56.14 (sold in multiple transactions).
- Shares disposed: 9,099; total proceeds ≈ $508,454.
- Shares owned after transaction: Not specified on the Form 4; filing notes the Reporting Person and family vehicles hold exchangeable interests equal to 2,474,120 Class A shares (RPI US Partners 2019, LP) and 1,356,528 Class A shares (via Class E shares of RPH, which are subject to vesting).
- Footnotes: F1 — sales were effected pursuant to a 10b5-1 trading plan adopted Feb 12, 2026. F2 — reported price is a weighted average; holder can provide a per-trade breakdown on request.
- Transaction type: Sale (S). No indication of late filing.
Context
This was a sale executed under a 10b5-1 plan, which indicates a prearranged trading schedule rather than an ad hoc decision; such sales are often routine and for liquidity or diversification. The filing also discloses significant exchangeable interests controlled by Marshall and family vehicles, some of which are subject to vesting conditions.
Insider Transaction Report
- Sale
Class A Ordinary Shares
[F1][F2]2026-07-01$55.88/sh−9,099$508,454→ 0 total
- 19,020(indirect: By IRA)
Class A Ordinary Shares
Footnotes (2)
- [F1]All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on February 12, 2026.
- [F2]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.69 to $56.14 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.